Physician profile
Don E Heinkel
NPI 1396738761
$9,480.21
in general payments reported to CMS, 2019-2025
45 companies · $933 in 2025
The $933 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $1,673 · 2021: $2,283 · 2022: $1,420 · 2023: $1,278 · 2024: $751 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,028.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,197.26 | 2020-2024 | Mounjaro, Emgality, Jardiance |
| Abbvie INC. | $782.68 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $708.61 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amarin Pharma, INC. | $496.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $468.84 | 2019-2025 | Trintellix |
| Pfizer INC. | $436.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $399.14 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $389.28 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $334.17 | 2019-2022 | |
| Astellas Pharma US INC | $262.62 | 2020-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $221.28 | 2021-2025 | |
| Horizon Therapeutics Plc | $154.43 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $151.87 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $123.15 | 2020-2024 | Linzess |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Heinkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.